Structuring a deal in the life sciences sector remains challenging: Investment regimes, regulatory framework, cost pressure on R&D activities, evolving commercial models and rising costs of healthcare require in-depth legal and industry know-how.

Members of our Mergers & Acquisitions and Life Sciences practice groups  - Lorenza Ferrari Hofer, Pascal Hubli, Marcel Jakob and Oliver Triebold - presented and discussed legal questions arising out of life sciences transactions, with a focus on venture deals, stock exchange listings, and the regulatory framework.